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ABSTRACT
In recent times, there has been an increase in drug abuse in the general population
and in women of reproductive age. Our objectives were to identify, classify, and
describe the spectrum of complications, the average number of admissions, and the
length of hospital stay among pregnant women with substance abuse. The aim was
to understand complication prevalence better to improve management in this evergrowing population. A retrospective chart review was conducted of pregnant women
ages 18-45 with a history of substance abuse from 2013-2018 in the tri-state area of
West Virginia, Ohio, and Kentucky. We collected the following data: demographics,
medical history, specific substances abused, inpatient admission dates and diagnoses,
and delivery information. A total of 411 patients met the inclusion criteria, comprising
525 pregnancies. Out of 525 pregnancies, 71.6 % used buprenorphine (i.e., Subutex),
43.4% used opiates (excluding heroin), and 35% of patients used heroin. Out of the
525 pregnancies, there were 714 inpatient antepartum admissions. Of these, 376
were admissions due to withdrawal symptoms (52.7%). A total of 263 pregnancies
had at least one admission for withdrawal, drug abuse, overdose, or buprenorphine/
methadone conversion (50%). The average hospital stay for withdrawal admissions was
3.4 days (SD). There were 62 admissions for infectious causes, 24 due to pyelonephritis
(38.7%). The findings highlight multiple areas for future studies and areas for quality
improvement in managing this population.
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INTRODUCTION
In recent times, there has been an increase in drug
abuse in the general population and in women
of reproductive age. According to data compiled
by the Yale School of Medicine, women are most
likely to develop a problem with substance abuse
between the ages of 18 and 29, with 5.9% of the total
female population of the United States using illicit
substances in 2012. Between 2000 and 2009, the
US saw an increase of 5 times for women abusing
opioids during pregnancy.1
According to the CDC, West Virginia leads the United
States in overdose deaths with a rate of 52.0 per
100,000.2 There has been a rapid increase in health
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care costs and burden to the existing healthcare
system in treating and caring for these patients.
Of note, the rate of babies born with neonatal
abstinence syndrome rose from 25.2 per 1,000 births
in WV to 51.2 per 1,000 births between 2011 and
2014, as reported by the NIH, and has likely trended
higher since then.3 These children and their mothers,
whom both face withdrawal from illicit substances,
have become an increasing proportion of the patient
population.
Twenty-four percent of pregnant women can
achieve future abstinence due to their pregnancy.
The remainder relapse during the postnatal period
and, as noted above, often are of an age that they
may again become pregnant while suffering from
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substance abuse.4 In Huntington, West Virginia, one
medication-assisted treatment (MAT) program for
pregnant women that has tried to combat this is the
Maternal Addiction and Recovery Center (MARC).
MARC provides obstetrical care, outpatient addiction
care, and counseling for pregnant patients with
opiate addiction. MARC focuses on the health and
safety of mothers with substance use disorders and
their babies throughout pregnancy with medical
care, counseling, and a built-in support network.
Guidelines have been designed that focus on the
psychosocial aspect of helping those who suffer from
substance abuse in pregnancy; in this vein, there is a
fair amount of research aimed at discovering novel
means of improving the quality of life of both the
mother and fetus in the perinatal period. However,
a frank discussion of the effects on maternal health
is often overshadowed by the damage done to
the future neonate.5 Very little data is currently
compiled on the complications of substance abuse
in pregnancy. In this retrospective chart review,
our goal was to identify, classify, and describe the
spectrum of complications, the average number of
admissions, and the length of hospital stay among
pregnant women who suffer from substance abuse.
We aim to provide a better understanding of
prevalence in order to improve management in this
ever-growing subset of the population.
Methods

describe the spectrum of complications, the average
number of admissions, and the length of hospital
stay that occur among pregnant women with
substance abuse. We also looked at the differences
in those subjects based on if the patient was in the
MARC program or not. The aim was to understand
complication prevalence better to improve
management in this ever-growing population.
RESULTS
A total of 411 patients met the inclusion criteria.
There were 525 pregnancies and deliveries, with an
age range of 18-44 and a mean age of 27.59 (SD 4.7).
A total of 314 patients had one delivery, 78 patients
had two deliveries, 17 patients had three deliveries,
and 1 patient had four deliveries during the study
period. Most patients were Caucasian (96.4%), 4
patients were African American (0.97%), and 11
were not recorded (2.4%). Out of 525 pregnancies,
71.6% used buprenorphine, followed by 43.4%
using opiates (excluding heroin) (Table 1). Of 525

This study involved a retrospective chart review
of pregnant women with known substance abuse
during pregnancy identified via ICD-10 diagnosis
codes. Inclusion criteria were as follows: current and/
or history of substance abuse, pregnant during the
study period of 2013-2018, and age range of 1845. Data collected included subject demographics,
medical history, individual substances being abused,
inpatient admission information, and delivery
information. Admission information obtained
included the date of admission, date of discharge,
length of hospital stays, and the diagnosis for
admission. The labor and delivery information
obtained included delivery mode, complications,
and whether the neonate was admitted to the NICU
or NTU. It was also recorded whether subjects were
established within the institution’s MARC program at
the time of each admission.
The primary outcomes were to identify, classify, and
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TABLE 1. Substances used and medical comorbidities
among 525 deliveries in a cohort of 411 patients.
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deliveries, the two most common comorbidities
pregnancies were patients in the MARC program.
were hepatitis C and depression, 59.2% and 38.7%,
There were 279 not in the MARC program and 25
respectively (Table 1).
undocumented. A total of 127 (57.5%) patients in
Out of 525 pregnancies, there were 714 inpatient
the MARC program were admitted for withdrawal,
antepartum admissions, i.e., admissions not
compared to a total of 121 (43.5%) non-MARC
including the labor and delivery inpatient admission.
patients admitted for withdrawal (p=0.001). There
Overwhelmingly, the common reason for admission
was withdrawal. Of the 714 antepartum admissions,
376 (52.7%) were due to withdrawal, drug abuse,
overdose, or buprenorphine/methadone conversion.
263 (50%) of the 525 pregnancies had at least one
admission for withdrawal, drug abuse, overdose,
or buprenorphine/methadone conversion. The
remainder of the antepartum admissions were as
follows: 62 (8.75%) for infectious causes, 19 (2.7%)
for psych/social circumstances, 28 (3.9%) for nonreassuring antenatal testing (abnormal biophysical
profile, fetal deceleration, nonreactive strip, etc.),
and the remaining 229 (31.95%) admissions were for
maternal/fetal indications, such as preterm pre-labor FIGURE 1. Number of antepartum admissions of any cause
rupture of membranes, preterm labor, placental
(not including delivery) among 525 pregnancies with
abruption, etc.
substance use. Three hundred and eighty patients out of
As noted, there were 62 admissions for
infectious causes. Of these, 24 (38.7%) were due
to pyelonephritis, and 9 (14.5%) were due to
pneumonia. There were 8 (12.9%) from sepsis,
including endocarditis, septic emboli, or joints, and
9 (14.5%) from soft tissue abscesses. The remaining
were from less common sources of infection, such as
cellulitis or dental abscesses.
Out of the 525 patients, 145 (27.6%) had no
antepartum admissions, 221 (42.1%) had one
admission, and the remaining patients were
admitted more than once, with a small number
of patients having between 4-12 antepartum
admissions (Figure 1). The number of admissions
relating specifically to withdrawal, conversion, or
drug abuse ranged from 1 to 5 (Figure 2). There
was a high variation in the length of stay for any
antepartum admission. Admission length ranged
from less than 1 day to 82 days. Patients with
extreme length of stay were primarily complicated
by infectious causes requiring extensive intravenous
antibiotic use. When specifically looking at
admissions for drug abuse or withdrawal, the
average length of inpatient stay was 3.4 days.
Two hundred and twenty-one out of the 525
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the 525 pregnancies had at least 1 antepartum admission.
Two hundred and twenty-one patients had 1 antepartum
admission. Eighty patients had 2 admissions. Thirty-five
patients had 3 admissions. Twenty-three patients had
4 admissions. Twelve patients had 5 admissions. Three
patients had 6 admissions. One patient had 7 admissions.
Two patients had 9 admissions. Three separate individual
patients each had 10, 11, and 12 admissions.

FIGURE 2. Number of admissions for withdrawal, conversion, or drug abuse among 525 pregnancies with substance
use. Of the 263 admissions related to withdrawal, conversion, or drug abuse among the 525 pregnancies with substance use, 203 patients were admitted 1 time, 36 patients
were admitted 2 times, 15 patients were admitted 3 times, 7
patients were admitted 4 times, and 2 patients were admitted 5 times.
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was no difference between groups in the mean
number of antepartum admissions for withdrawal or
average length of stay (Table 2).
Out of the 525 pregnancies, delivery data was
obtained on 433 patients (Table 3). A total of 118
(27.2%) infants were admitted to the neonatal
intensive care unit (NICU). A total of 85 (19.6%)

TABLE 2. Comparison of patients within the Maternal
Addiction Recovery Center (MARC) and not regarding
admission for withdrawal, mean number of admissions,
and length of stay.

TABLE 3. Delivery data on 525 pregnancies with
substance use
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infants were admitted to the neonatal therapeutic
unit (NTU). There was significant missing data on
NICU and NTU admissions.
DISCUSSION
This study highlights the spectrum of complications
and hospital admission data on a group of 411
patients with 525 pregnancies and deliveries with
known substance abuse. There were 714 antepartum
admissions, with over half of these attributed to
withdrawal symptoms (52.7%). The average inpatient
stay for these 376 withdrawal admissions was 3.4
days. With the average daily inpatient cost of a
hospital stay in the United States in the thousands,
these withdrawal-associated admissions are a
huge cost burden to consumers and taxpayers
alike. Per the American College of Obstetricians
and Gynecologists (ACOG), MAT with methadone
or buprenorphine in combination with counseling
and behavioral therapy is the standard treatment of
heroin addiction during pregnancy.6 During these
withdrawal admissions at our institution, patients
were typically transitioned to buprenorphine as the
first line agent for their MAT. One review of 18 studies
involving 63 patients transitioning to buprenorphine
using different microdosing techniques found
that most patients transitioned to a stable dose
of buprenorphine over a period of 4 to 8 days.7
To combat rising health care costs and societal
burden by decreasing the duration of hospital stay
for induction of buprenorphine, our institution is
currently trialing a rapid buprenorphine induction
process vs. the previous delayed induction process,
as was performed during this study period. With a
newer approach, we anticipate a decrease in the
average length of inpatient stay for withdrawal
admission from 3.4 days reported in this study by at
least 1 or more days; this decrease will potentially
save patients and the health care system thousands
of dollars.
A limitation of the study is that the timing of
entrance into the MARC program was not recorded.
There may be patients that were enrolled in the
MARC program prior to or after their inpatient
admissions for withdrawal symptoms. This is likely
why admissions for withdrawal in the MARC group
were statistically higher than those not in the MARC
group.
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The high rates of both depression and hepatitis C
among our patients with substance use disorder
are notable. Per ACOG, more than 30% of women
enrolled in MAT programs screened positive for
moderate to severe depression, and more than
40% screened positive for postpartum depression.6
This study continues to confirm the importance of
mental health screening, especially in these atrisk populations. Additionally, this study confirms
the increasing rate of hepatitis C among pregnant
patients. One previous study examining the
prevalence of the hepatitis C virus in women of
childbearing age and pregnant women in the United
States found that from 2011 to 2016, hepatitis C
virus rates increased by 39%, from 6.1% to 8.4% in
this population. They found that hepatitis C virus
rates among pregnant women increased by 135%,
from 5.7% to 13.4%.8 As of May 2021, ACOG is now
recommending screening for hepatitis C for all
pregnant individuals during each pregnancy.9
Of the 714 antepartum admissions, 62 (8.75%) were
for infectious causes, with 38.7% of these admissions
attributable to pyelonephritis. The incidence
of pyelonephritis in pregnancy is estimated to
be between 0.5 to 2%.10 This warrants future
investigation to potentially reduce this increased rate
of kidney infections in this at-risk population.
In this retrospective chart review, our goal was
to identify, classify, and describe the spectrum
of complications and the average number of
admissions and length of hospital stay among
pregnant women who suffer from substance abuse.
We aimed to provide a better understanding of
prevalence in order to improve management in this
ever-growing subset of the population. This study
has given background information on a population
lacking much data and will hopefully contribute to
many quality improvement measures in the future.
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